We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
WAINUA (AstraZeneca Pty Ltd)
Product name
WAINUA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
171 (255 working days)
Active ingredients
eplontersen sodium
Registration type
NCE/NBE
Indication
WAINUA is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.